Three biotechs priced upsized initial public offerings, raising more than $850 million combined, according to market reporting. The batch included Seaport Therapeutics and Hemab Therapeutics, alongside another company entering the market with improved aftermarket performance. Hemab Therapeutics priced its IPO at $18 per share for gross proceeds of $301.5 million, targeting coagulation disorders. Seaport Therapeutics raised gross proceeds of $254.9 million as it debuted on the Nasdaq after filing and listing steps tied to its corporate structure. The financing activity signals sustained investor appetite for publicly listed biotech platforms, particularly those with clear regulatory milestones or differentiated technology positioning.